Actuate Therapeutics, Inc. Common stock (ACTU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Actuate Therapeutics, Inc. Common stock (ACTU) has a cash flow conversion efficiency ratio of -0.611x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.68 Million) by net assets ($10.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Actuate Therapeutics, Inc. Common stock book value and equity for net asset value and shareholders' equity analysis.
Actuate Therapeutics, Inc. Common stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Actuate Therapeutics, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Actuate Therapeutics, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actuate Therapeutics, Inc. Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gaia Inc
NASDAQ:GAIA
|
0.015x |
|
Airmate Cayman International Co Ltd
TW:1626
|
-0.074x |
|
Batm Advanced Communications Ltd
TA:BVC
|
-0.054x |
|
Shree Rama Newsprint Limited
NSE:RAMANEWS
|
0.111x |
|
Dae Hyun
KO:016090
|
0.002x |
|
Nh Prime Reit Co Ltd
KO:338100
|
N/A |
|
Adveritas Ltd
AU:AV1
|
-1.106x |
|
PT Ingria Pratama Capitalindo Tbk
JK:GRIA
|
0.071x |
Annual Cash Flow Conversion Efficiency for Actuate Therapeutics, Inc. Common stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see ACTU market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $104.19K | $-21.84 Million | -209.651x | -96685.38% |
| 2023-12-31 | $-99.63 Million | $-21.63 Million | 0.217x | +118.09% |
| 2022-12-31 | $14.83 Million | $-17.79 Million | -1.200x | -- |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more